Telehealth after the pandemic: Will the inverse care law apply? (Commentary)

Rebecca J. Calthorpe; Alan R. Smyth

doi:10.1016/j.jcf.2021.08.023

Telehealth after the pandemic: Will the inverse care law apply? (Commentary)

Rebecca J. Calthorpe^*
, Alan R. Smyth

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

16 Downloads (Pure)

Abstract

The COVID-19 pandemic has accelerated the use of telehealth within the cystic fibrosis (CF) community to deliver CF care. The article by Solomon and colleagues exploring the patient and family experiences of telehealth care delivery, as part of the CF chronic care model in the US, is therefore timely. In this commentary, we discuss how the US experience of telehealth care compares with reports from CF centres in other parts of the world. We highlight the potential challenges, including whether the inverse care law will apply in this new era of CF telehealth.

Original language	English
Pages (from-to)	47-48
Number of pages	2
Journal	Journal of Cystic Fibrosis
Volume	20
Issue number	Supplement 3
DOIs	https://doi.org/10.1016/j.jcf.2021.08.023
Publication status	Published - 18 Dec 2021
Externally published	Yes

Bibliographical note

Funding Information:
We would like to thank Dr G. Connett, University Hospital Southampton NHS Foundation Trust, for access and use of the UK Cystic Fibrosis Medical Association 2020 survey data included within this commentary. This paper is part of a Supplement supported by the Cystic Fibrosis Foundation.

Funding Information:
R.C has no conflicts of interest. Outside the submitted work, A.S reports grants from Vertex and reports speaker honoraria and expenses from TEVA and Vertex. A.S reports membership of the US CF Foundation therapeutic development network data safety monitoring board. A.R. Smyth has a patent “Alkyl quinolones as biomarkers of Pseudomonas aeruginosa infection and uses thereof” issued.

Publisher Copyright:
© 2021

Keywords

COVID-19
Cystic fibrosis
Telehealth
Telemedicine

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.jcf.2021.08.023Licence: CC BY-NC-ND

Telehealth after the pandemic: Will the inverse care law apply? (Commentary)
Copyright 2021 the authors. This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Final published version, 253 KBLicence: CC BY-NC-ND

Cite this

@article{7aa64fe114934c56a01714cc4fd628f8,

title = "Telehealth after the pandemic: Will the inverse care law apply? (Commentary)",

abstract = "The COVID-19 pandemic has accelerated the use of telehealth within the cystic fibrosis (CF) community to deliver CF care. The article by Solomon and colleagues exploring the patient and family experiences of telehealth care delivery, as part of the CF chronic care model in the US, is therefore timely. In this commentary, we discuss how the US experience of telehealth care compares with reports from CF centres in other parts of the world. We highlight the potential challenges, including whether the inverse care law will apply in this new era of CF telehealth.",

keywords = "COVID-19, Cystic fibrosis, Telehealth, Telemedicine",

author = "Calthorpe, \{Rebecca J.\} and Smyth, \{Alan R.\}",

note = "Funding Information: We would like to thank Dr G. Connett, University Hospital Southampton NHS Foundation Trust, for access and use of the UK Cystic Fibrosis Medical Association 2020 survey data included within this commentary. This paper is part of a Supplement supported by the Cystic Fibrosis Foundation. Funding Information: R.C has no conflicts of interest. Outside the submitted work, A.S reports grants from Vertex and reports speaker honoraria and expenses from TEVA and Vertex. A.S reports membership of the US CF Foundation therapeutic development network data safety monitoring board. A.R. Smyth has a patent “Alkyl quinolones as biomarkers of Pseudomonas aeruginosa infection and uses thereof” issued. Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = dec,

day = "18",

doi = "10.1016/j.jcf.2021.08.023",

language = "English",

volume = "20",

pages = "47--48",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier B.V.",

number = "Supplement 3",

}

TY - JOUR

T1 - Telehealth after the pandemic: Will the inverse care law apply? (Commentary)

AU - Calthorpe, Rebecca J.

AU - Smyth, Alan R.

N1 - Funding Information: We would like to thank Dr G. Connett, University Hospital Southampton NHS Foundation Trust, for access and use of the UK Cystic Fibrosis Medical Association 2020 survey data included within this commentary. This paper is part of a Supplement supported by the Cystic Fibrosis Foundation. Funding Information: R.C has no conflicts of interest. Outside the submitted work, A.S reports grants from Vertex and reports speaker honoraria and expenses from TEVA and Vertex. A.S reports membership of the US CF Foundation therapeutic development network data safety monitoring board. A.R. Smyth has a patent “Alkyl quinolones as biomarkers of Pseudomonas aeruginosa infection and uses thereof” issued. Publisher Copyright: © 2021

PY - 2021/12/18

Y1 - 2021/12/18

N2 - The COVID-19 pandemic has accelerated the use of telehealth within the cystic fibrosis (CF) community to deliver CF care. The article by Solomon and colleagues exploring the patient and family experiences of telehealth care delivery, as part of the CF chronic care model in the US, is therefore timely. In this commentary, we discuss how the US experience of telehealth care compares with reports from CF centres in other parts of the world. We highlight the potential challenges, including whether the inverse care law will apply in this new era of CF telehealth.

AB - The COVID-19 pandemic has accelerated the use of telehealth within the cystic fibrosis (CF) community to deliver CF care. The article by Solomon and colleagues exploring the patient and family experiences of telehealth care delivery, as part of the CF chronic care model in the US, is therefore timely. In this commentary, we discuss how the US experience of telehealth care compares with reports from CF centres in other parts of the world. We highlight the potential challenges, including whether the inverse care law will apply in this new era of CF telehealth.

KW - COVID-19

KW - Cystic fibrosis

KW - Telehealth

KW - Telemedicine

U2 - 10.1016/j.jcf.2021.08.023

DO - 10.1016/j.jcf.2021.08.023

M3 - Article

C2 - 34521596

AN - SCOPUS:85114712185

SN - 1569-1993

VL - 20

SP - 47

EP - 48

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

IS - Supplement 3

ER -

Telehealth after the pandemic: Will the inverse care law apply? (Commentary)

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this